XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer

被引：27
|
作者：
Feng, Jifeng [2 ,3 ]
Sun, Xinchen [1 ]
Sun, Ning [1 ]
Qin, Shukui [4 ]
Li, Fan [1 ]
Cheng, Hongyan [1 ]
Chen, Baoan [1 ]
Cao, YuanDong [1 ]
Ma, Jun [1 ]
Cheng, Lu [5 ]
Lu, Zuhong [5 ]
Ji, Jiazhong [6 ]
Zhou, Yingfeng [6 ]
机构：
[1] Southeast Univ, Zhongda Hosp, Nanjing 210009, Peoples R China
[2] Southeast Univ, Sch Med, Nanjing 210009, Peoples R China
[3] Jiangsu Canc Hosp, Nanjing 210009, Peoples R China
[4] PLA, Hosp 81, Dept Oncol, Nanjing 210034, Peoples R China
[5] Southeast Univ, Lab Mol & Biomol Elect, Nanjing 210096, Peoples R China
[6] Jiangbei People Hosp, Dept Oncol, Nanjing 210048, Peoples R China
来源：
ACTA BIOCHIMICA ET BIOPHYSICA SINICA | 2009年 / 41卷 / 05期
关键词：
single nucleotide polymorphism; gene-chip; XPA; XPG; nucleotide excision repair; non-small cell lung cancer; chemotherapy; NUCLEOTIDE-EXCISION-REPAIR; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; DNA-REPAIR; GROUP-A; TRANSCRIPTION; RISK; BINDING; ERCC1; RNA;
D O I：
10.1093/abbs/gmp027
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A -> G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
引用
收藏
页码：429 / 435
页数：7
相关论文
共 50 条
  • [31] Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Wenheng
    Mao, Yan
    Zhan, Yongzi
    Huang, Jianheng
    Wang, Xiangping
    Luo, Penghui
    Li, Li
    Mo, Dunchang
    Liu, Qiong
    Xu, Huimin
    Huang, Changjie
    [J]. ONCOLOGY LETTERS, 2016, 11 (01) : 723 - 730
  • [32] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Hirotsugu Kenmotsu
    Tateaki Naito
    Keita Mori
    Ryo Ko
    Akira Ono
    Kazushige Wakuda
    Hisao Imai
    Tetsuhiko Taira
    Haruyasu Murakami
    Masahiro Endo
    Toshiaki Takahashi
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 521 - 526
  • [33] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Mori, Keita
    Ko, Ryo
    Ono, Akira
    Wakuda, Kazushige
    Imai, Hisao
    Taira, Tetsuhiko
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 521 - 526
  • [34] Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Sullivan, Ivana
    Salazar, Juliana
    Majem, Margarita
    Pallares, Cinta
    del Rio, Elisabeth
    Paez, David
    Baiget, Montserrat
    Barnadas, Agusti
    [J]. CANCER LETTERS, 2014, 353 (02) : 160 - 166
  • [35] The power of immunotherapy plus platinum-based chemotherapy for locally advanced or early stage non-small cell lung cancer
    Hofman, Paul
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (05)
  • [36] Randomized trial of feiyanning decoction in combination with platinum-based chemotherapy in advanced non-small cell lung cancer patients
    Xu, Z.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S493 - S493
  • [37] Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer
    Yoh, K
    Ishii, G
    Yokose, T
    Minegishi, Y
    Tsuta, K
    Goto, K
    Nishiwaki, Y
    Kodama, T
    Suga, M
    Ochiai, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (05) : 1691 - 1697
  • [38] EVALUATION OF THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Okada, Asuka
    Fukuoka, Kazuya
    Okuwa, Hisaya
    Kamiya, Hitomi
    Honda, Miki
    Masachika, Eriko
    Otsuki, Taiichiro
    Maeda, Risa
    Hirayama, Noriko
    Terada, Takayuki
    Murakami, Aki
    Yamada, Syusai
    Tamura, Kuninobu
    Tabata, Chiharu
    Nakano, Takashi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1202 - S1203
  • [39] NANOG Predicts Poor Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Lee, Seung Hyeun
    Park, Myung Jae
    Park, So Young
    In, Kwang Ho
    Kim, Chul Hwan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S959 - S960
  • [40] Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer
    Hongying Lv
    Ting Han
    Xiaoli Shi
    Yasai Yao
    Yongru Yao
    Wensheng Qiu
    Lu Yue
    Jun Liang
    [J]. Medical Oncology, 2014, 31
12345